The global parenteral nutrition market size was estimated at USD 7.97 billion in 2025 and is projected to reach USD 12.59 billion by 2033, growing at a CAGR of 5.87% from 2026 to 2033. This growth is attributed to the rising prevalence of gastrointestinal disorders, increasing premature births, and the growing incidence of chronic diseases such as cancer.
Expanding hospital infrastructure, advancements in nutrient formulations, and increasing adoption of home parenteral nutrition further support market growth globally. Moreover, the rising prevalence of chronic conditions, particularly cancer and disease-related malnutrition, is driving demand for parenteral nutrition, as these patients often experience gastrointestinal dysfunction or treatment-related complications that limit oral or enteral feeding. Cancer therapies such as chemotherapy and radiation frequently necessitate intravenous nutritional support; for instance, the National Cancer Institute estimates 2,114,850 new cancer cases and 626,140 cancer deaths in the U.S. in 2026, highlighting the growing patient base requiring parenteral nutrition.
Numerous benefits accompany parenteral nutrition, including ease of use, stimulation of stomach blood flow, efficient nutrient delivery, and preservation of muscle catabolism. Globally, various health awareness campaigns, with a particular emphasis on nutrition, are underway, along with diverse initiatives promoting health and social care, expected to bolster market growth. For example, India observed POSHAN Maah in September 2023, mirroring the Government of India's flagship program, POSHAN Abhiyaan, aimed at raising awareness and enhancing nutritional outcomes for pregnant women, children under six years of age, and lactating mothers.
PN also has applications for infants and children suffering from a disease or medical condition, thereby requiring special nutritional management. In 2023, Specialized Nutrition Europe (SNE) estimated that nearly 300,000 EU children are anticipated to require medical nutrition for their special medical needs in early life stages, which supports growth and development. The study further reveals that about 40% of hospitalized adult patients are malnourished and need medical nutrition to manage the disease-related malnutrition condition, thereby reducing the duration of hospital stay. PN lowers the infection risk and underdevelopment, thereby promoting its adoption worldwide.
Parenteral nutrition providers are increasingly focusing on ready-to-use multi-chamber bags, advanced lipid emulsions, and patient-specific formulations to improve safety, efficiency, and clinical outcomes. Companies like Baxter and Fresenius Kabi offer specialized solutions such as Numeta for neonates, Kabiven for adults, and SMOFlipid/Omegaven lipid emulsions enriched with mixed oils and omega-3s to support metabolic function and reduce complications. There is also a growing emphasis on tailored neonatal and pediatric PN, home parenteral nutrition, and streamlined infusion workflows, reflecting the industry’s shift toward protocol-driven, patient-centric nutrition management across hospital and outpatient settings.
Many premature babies experience low weight and underdeveloped immunity, placing them at significant risk. There is extensive focus from individuals and healthcare authorities on reducing mortality associated with preterm birth, which drives the utilization of parenteral lipid emulsions. According to the U.S. Centers for Disease Control and Prevention (CDC), the preterm birth rate in the country was approximately 10.4% in 2022. In addition, during the same period, the preterm birth rate for African American women was around 14.6%. These elevated preterm birth rates are expected to bolster market expansion.
This product will be delivered within 1-3 business days.
Expanding hospital infrastructure, advancements in nutrient formulations, and increasing adoption of home parenteral nutrition further support market growth globally. Moreover, the rising prevalence of chronic conditions, particularly cancer and disease-related malnutrition, is driving demand for parenteral nutrition, as these patients often experience gastrointestinal dysfunction or treatment-related complications that limit oral or enteral feeding. Cancer therapies such as chemotherapy and radiation frequently necessitate intravenous nutritional support; for instance, the National Cancer Institute estimates 2,114,850 new cancer cases and 626,140 cancer deaths in the U.S. in 2026, highlighting the growing patient base requiring parenteral nutrition.
Numerous benefits accompany parenteral nutrition, including ease of use, stimulation of stomach blood flow, efficient nutrient delivery, and preservation of muscle catabolism. Globally, various health awareness campaigns, with a particular emphasis on nutrition, are underway, along with diverse initiatives promoting health and social care, expected to bolster market growth. For example, India observed POSHAN Maah in September 2023, mirroring the Government of India's flagship program, POSHAN Abhiyaan, aimed at raising awareness and enhancing nutritional outcomes for pregnant women, children under six years of age, and lactating mothers.
PN also has applications for infants and children suffering from a disease or medical condition, thereby requiring special nutritional management. In 2023, Specialized Nutrition Europe (SNE) estimated that nearly 300,000 EU children are anticipated to require medical nutrition for their special medical needs in early life stages, which supports growth and development. The study further reveals that about 40% of hospitalized adult patients are malnourished and need medical nutrition to manage the disease-related malnutrition condition, thereby reducing the duration of hospital stay. PN lowers the infection risk and underdevelopment, thereby promoting its adoption worldwide.
Parenteral nutrition providers are increasingly focusing on ready-to-use multi-chamber bags, advanced lipid emulsions, and patient-specific formulations to improve safety, efficiency, and clinical outcomes. Companies like Baxter and Fresenius Kabi offer specialized solutions such as Numeta for neonates, Kabiven for adults, and SMOFlipid/Omegaven lipid emulsions enriched with mixed oils and omega-3s to support metabolic function and reduce complications. There is also a growing emphasis on tailored neonatal and pediatric PN, home parenteral nutrition, and streamlined infusion workflows, reflecting the industry’s shift toward protocol-driven, patient-centric nutrition management across hospital and outpatient settings.
Many premature babies experience low weight and underdeveloped immunity, placing them at significant risk. There is extensive focus from individuals and healthcare authorities on reducing mortality associated with preterm birth, which drives the utilization of parenteral lipid emulsions. According to the U.S. Centers for Disease Control and Prevention (CDC), the preterm birth rate in the country was approximately 10.4% in 2022. In addition, during the same period, the preterm birth rate for African American women was around 14.6%. These elevated preterm birth rates are expected to bolster market expansion.
Global Parenteral Nutrition Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global parenteral nutrition market report based on nutrient type, stage type, indication, sales channel, and region:Nutrient Type Outlook (Revenue, USD Million, 2021-2033)
- Carbohydrates
- Parenteral Lipid Emulsion
- Single Dose Amino Acid Solution
- Trace Elements
- Vitamins & Minerals
Stage Type Outlook (Revenue, USD Million, 2021-2033)
- Adult
- Pediatrics
Indication Outlook (Revenue, USD Million, 2021-2033)
- Alzheimer’s
- Nutrition Deficiency
- Cancer Care
- Diabetes
- Chronic Kidney Diseases
- Orphan Diseases
- Dysphagia
- Pain Management
- Malabsorption/GI Disorder/Diarrhea
- Others
Sales Channel Outlook (Revenue, USD Million, 2021-2033)
- Online
- Retail
- Institutional
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Norway
- Denmark
- Asia Pacific
- China
- India
- Japan
- Thailand
- Australia
- South Korea
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Parenteral Nutrition Market Variables, Trends, & Scope
Chapter 4. Parenteral Nutrition Market: Nutrient Type Estimates & Trend Analysis
Chapter 5. Parenteral Nutrition Market: Stage Type Estimates & Trend Analysis
Chapter 6. Parenteral Nutrition Market: Indication Estimates & Trend Analysis
Chapter 7. Parenteral Nutrition Market: Sales Channel Estimates& Trend Analysis
Chapter 8. Parenteral Nutrition Market: Regional Estimates & Trend Analysis by Country, Nutrient Type, Stage Type, Indication, and Sales Channel
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Baxter
- Otsuka Pharmaceutical Factory, Inc.
- Grifols, S.A.
- B. Braun Melsungen AG
- Vifor Pharma (Acquired by CSL)
- Fresenius Kabi AG
- Sichuan Kelun Pharmaceutical Co., Ltd.
- Pfizer Inc. (Hospira Inc.)
- ICU Medical, Inc.
- JW Pharmaceutical
- Aculife
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 190 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 7.97 Billion |
| Forecasted Market Value ( USD | $ 12.59 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
